Clinical, anamnestic and laboratory studies as the basis of criteria for the prognosis of polypous rhinosinusitis

Introduction. Modern methods of treating polypous rhinosinusitis improve the patient’s quality of life, but they do not always allow predicting the outcome of the disease. In this context, the issues of predicting relapses remain open and require in-depth study and the formation of an evidence base.

Aim. To analyze the clinical, anamnestic and laboratory data of patients to form the basis of the criteria for the prognosis of polypous rhinosinusitis.

Materials and methods. The study included 240 subjects who, based on the biomarker, were divided into 2 groups: group 1: patients with Th2-mediated polypous rhinosinusitis; group 2: patients with non-Th2-mediated polypous rhinosinusitis. Anamnesis assessment was recorded through a questionnaire, clinical complaints and the level of quality of life were recorded using the SNOT-22 questionnaire.

Results and discussion. Analysis of clinical and anamnestic data showed the highest incidence of polypous rhinosinusitis in the range from 46 to 60 years, the prevalence in men (60%) is more common than in women (40%). In 35.9% of cases of polypous rhinosinusitis, Th2-mediated type occurs with the presence of bronchial asthma, most often (18.2%) Bronchial asthma with a predominance of the allergic component J45.0. Rhinological symptoms have a significant impact on the subjective sphere of life of the examined individuals and, as a result, a pronounced effect of polypous rhinosinusitis (71.7 ± 6.06 points) on the quality of life of patients. Polypous rhinosinusitis, non-H2-mediated type, occurs in 24.7% of cases with a history of bronchial asthma, most often 14.4% non-allergic asthma J45.1. The experience of bronchial asthma is lower, due to the later onset. The severity of complaints leads to a moderate effect (65.1 ± 4.07 points) of polypous rhinosinusitis on the quality of life of patients.

Conclusion. The analysis of clinical, anamnestic and laboratory data of patients with polypous rhinosinusitis revealed the features of the clinical picture and their impact on the quality of life of patients, which can be the basis for an in-depth instrumental examination to assess the prognosis of polypous rhinosinusitis.

1. Kwah JH, Peters AT. Nasal polyps and rhinosinusitis. Allergy Asthma Proc. 2019;40(6):380–384. https://doi.org/10.2500/aap.2019.40.4252.

2. Пискунов ГЗ, Арефьева НА, Карпищенко СА, Карпова ЕП, Лопатин АС, Моисеева ЮП и др. Полипозный риносинусит: клинические рекомендации. 2022. 57 с. Режим доступа: https://rhinology.ru/wp-content/uploads/2022/10/ПРС-Клинические_рекомендации_финал.pdf.

3. Баранов АА, Лобзин ЮВ, Намазова-Баранова ЛС, Таточенко ВК, Усков АН, Куличенко ТВ и др. Острая респираторная вирусная инфекция (ОРВИ): клинические рекомендации (проект). М.; 2020. 35 с. Режим доступа: https://www.pediatr-russia.ru/information/klin-rek/proektyklinicheskikhrekomendatsiy/ОРВИ%20дети%20СПР.v1_2019%20-%20финал.pdf.

4. Korkmazov MYu, Kazachkov EL, Lengina MA, Dubinets ID, Korkmazov AM. Cause-effect factors of rhinosinusitis poliposa development. Russian Rhinology. 2023;31(2):124–130. (In Russ.) https://doi.org/10.17116/rosrino202331021124.

5. Piskunov GZ. Clinical phenotypes of polyposis rhinosinusitis. Russian Rhinology. 2019;27(4):224–231. (In Russ.) https://doi.org/10.17116/rosrino201927041224.

6. Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023;61(3):194–202. https://doi.org/10.4193/Rhin22.489.

7. Savlevich EL, Pelishenko TG, Kozlov VS, Koryagin FN, Koryagina TS. Perioperative management of patients with operated nasal cavity and paranasal sinuses. Rossiiskaya Otorinolaringologiya. 2021;20(4):102–109. (In Russ.) https://doi.org/10.18692/1810-4800-2021-4-102-109

8. Shisheva AK, Korkmazov MY. Socio-economic aspects hospital help optimization for patient with pathology of nose and paranasal sinuses in the large industrial city conditions. Vestnik Yuzhno-Uralskogo Gosudarstvennogo Universiteta. Seriya: Obrazovanie, Zdravookhranenie, Fizicheskaya Kultura. 2011;(26):62–66. (In Russ.) Available at: https://elibrary.ru/oghxwh.

9. Savlevich EL, Doroschenko NE, Slavinskaya IS, Farikov SE. Important factors of the inflammatory process in the o ropharynx and optimal treatment regimes selection. Meditsinskiy Sovet. 2017;(16):48–54. (In Russ.) https://doi.org/10.21518/2079-701X-2017-16-48-54.

10. Hopkins C. Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2019;381(1):55–63. https://doi.org/10.1056/NEJMcp1800215.

11. Savlevich EL, Gaganov EL, Egorov V I, Kurbacheva OM, Gerasimov AN, Shachnev KN. A comparative pilot study of antipov polosnogo chronic rhinosinusitis patients living in different geographical regions of the Russian Federation. Immunologiya. 2018;39(4):208–213. (In Russ.) Available at: https://elibrary.ru/ntjdkw.

12. Korkmazov MYu, Lengina MA, Korkmazov AM, Kravchenko AYu. Effect of post-COVID syndrome on the quality of life of patients with allergic rhinitis and eosinophilic phenotype of chronic polyposis rhinosinusitis. Medical Journal of the Russian Federation. 2023;29(4):277–290. (In Russ.) https://doi.org/10.17816/medjrf472079.

13. Korkmazov MYu, Lengina MA. The need for additional rehabilitation methods for patients with cochleo-vestibular dysfunction. Vestnik Oto-Rino-Laringologii. 2012;(S5):76–77. Available at: https://elibrary.ru/yncybq.

14. Stevens WW, Schleimer RP, Kern RC. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016;4(4):565–572. https://doi.org/10.1016/j.jaip.2016.04.012.

15. Mullol J, Azar A, Buchheit KM, Hopkins C, Bernstein JA. Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era. J Allergy Clin Immunol Pract. 2022;10(6):1434–1453.e9. https://doi.org/10.1016/j.jaip.2022.03.002.

16. Lengina MA, Korkmazov MYu, Karpov IA, Uchaev DA, Mochalov UA, Vojvodina PA et al. About the undesirable effects of targeted therapy of polypous rhinosinusitis. Russian Journal of Immunology. 2025;28(1):157–162. (In Russ.) https://doi.org/10.46235/1028-7221-16970-ota.

17. Krivopalov AA, Kryukov AI, Lengina MA, Korkmazov АM, Kornova NV. Epidemiology of polypous rhinosinusitis in a megalopolis with a developed heavy industry. Meditsinskiy Sovet. 2025;19(9):146–155. (In Russ.) https://doi.org/10.21518/ms2025-196.

18. Korkmazov MYu, Angelovich MS, Lengina MA, Belousov SYu. Clinical case of angiosarcoma of ethmoidal labyrinth and frontal sinus, issues of morphological verification of diagnosis. Vestnik Oto-Rino-Laringologii. 2022;87(4):102–106. (In Russ.) https://doi.org/10.17116/otorino202287041102.

19. Toppila-Salmi S, Reitsma S, Hox V, Gane S, Eguiluz-Gracia I, Shamji M et al. Endotyping in Chronic Rhinosinusitis-An EAACI Task Force Report. Allergy. 2025;80(1):132–147. https://doi.org/10.1111/all.16418.

20. Giesinger OA, Korkmazov AM, Korkmazov MYu. The state of antimicrobial protection factors of nasal secretions in patients operated on for curvature of the nasal septum in the early postoperative period. Russian Journal of Immunology. 2017;11(2):117–119. (In Russ.) Available at: https://rjsimmjn.rj/jojr/article/view/597.

21. Korkmazov MYu, Dubinets ID, Lengina MA, Korkmazov AM, Kornova NV, Ryabenko YuI. Distinct indexes of immunological reactivity in surgical alteration of ORL organs. Russian Journal of Immunology. 2022;25(2):201–206. (In Russ.) https://doi.org/10.46235/1028-7221-1121-DIO.

22. Talibov AKh, Korkmazov MYu, Lengina MA, Krivopalov AA, Grishaev NV. Personalized Approach to Improving the Quality of Life and Psychophysical Readiness of Weightlifters Through the Correction of Sensory and Vasomotor Disorders of ENT Organs. Human. Sport. Medicine. 2021;21(4):29–41. (In Russ.) Available at: https://hsm.susu.ru/hsm/ru/article/view/1595.

23. Korkmazov MYu, Lengina MA, Dubinets ID, Kravchenko AYu, Klepikov SV. Some immunological aspects of targeted therapy of polypous rhinosinusitis. Russian Journal of Immunology. 2023;26(3):301–306. (In Russ.) https://doi.org/10.46235/1028-7221-8955-sia.

24. Savlevich EL, Gaganov LV, Egorov VI, Kurbacheva OM, Mitrofanova ES, Pelishenko TG, Lyubimova EV. Application of eosinophil-neutrophil index eni and degree of inflammatory infiltration to assess the inflammatory process in polypous rhinosinusitis. Rossiiskaya Otorinolaringologiya. 2022;21(5):70–81. (In Russ.) https://doi.org/10.18692/1810-4800-2022-5-70-81.

25. Korkmazov AM. The topical issues of the treatment of the patients presenting with rhinosurgical problems during the early postoperative period. Russian Rhinology. 2018;26(1):38–42. (In Russ.) https://doi.org/10.17116/rosrino201826138-42.

26. Popadyuk VI, Karpov IA, Lengina MA, Korkmazov AM, Kornova NV. Seawater with silver ions in the elimination therapy of polypous sinusitis. Meditsinskiy Sovet. 2025;19(7):46–53. (In Russ.) https://doi.org/10.21518/ms2025-133.

27. Pearlman AN, Chandra RK, Chang D, Conley DB, Tripathi-Peters A, Grammer LC et al. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am J Rhinol Allergy. 2009;23(2):145–148. https://doi.org/10.2500/ajra.2009.23.3284.

28. Savlevich EL, Kurbacheva OM. Features of the course of polypous rhinosinusitis combined with allergic rhinitis. Meditsinskiy Sovet. 2019;(20):38–43. (In Russ.) https://doi.org/10.21518/2079-701X-2019-20-38-43.

29. Grigoreas C, Vourdas D, Petalas K, Simeonidis G, Demeroutis I, Tsioulos T. Nasal polyps in patients with rhinitis and asthma. Allergy Asthma Proc. 2002;23(3):169–174. Available at: https://pubmed.ncbi.nlm.nih.gov/12125503.

30. Savlevich EL, Zurochka AV, Kurbacheva OM, Egorov VI, Shilovskiy IP, Mitrofanova ES, Lyubimova EV. Pleiomorphism of the cytokine profile in nasal polyp tissue depending on the phenotype of chronic rhinosinusitis with nasal polyps. Vestnik Oto-Rino-Laringologii. 2023;88(1):50–56. (In Russ.) https://doi.org/10.17116/otorino20228801150.

31. Savlevich EL, Lyubimova EV, Zurochka AV, Mitrofanova ES, Shilovskiy IP. Cytokine profile of nasal polyps and clinical characteristics of patients with polypous rhinosinisitis at different degree of therapeutic control and disease severity. Medical Immunology (Russia). 2024;26(3):533–544. (In Russ.) https://doi.org/10.15789/1563-0625-CPO-2914.

32. Korkmazov MYu. Chronic tonsillitis and analysis of physical methods of exposure. Vestnik Oto-Rino-Laringologii. 2006;(S5):299–300. (In Russ.) Available at: https://elibrary.ru/sicbel.

33. Korkmazov MYu, Yastremsky AP, Kornova NV, Lengina MA, Korkmazov AM. Therapeutic and diagnostic approaches in the treatment of chronic tonsillitis. Meditsinskiy Sovet. 2022;16(20):90–99. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-20-90-99.

34. Grayson JW, Li W, Ho J, Alvarado R, Rimmer J, Sewell WA, Harvey RJ. Topography of polyp recurrence in eosinophilic chronic rhinosinusitis. Int Forum Allergy Rhinol. 2020;10(5):604–609. https://doi.org/10.1002/alr.22529.

35. Dubinets ID, Korkmazov MY, Korkmazov AM, Sinitskii AI, Mokina MV. Personalized prediction of the results of reconstructive surgery for chronic otitis media. Meditsinskiy Sovet. 2022;16(4):146–155. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-4-146-155.

36. Янов ЮК, Крюков АИ, Дворянчиков ВВ, Носуля ЕВ (ред.). Оториноларингология: национальное руководство. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2024. 992 с. Режим доступа: https://www.rosmedlib.ru/sl/book/ISBN9785970482131.html.

37. Lavigne F, Miller SK, Gould AR, Lanier BJ, Romett JL. Steroid-eluting sinus implant for in-office treatment of recurrent nasal polyposis: a prospective, multicenter study. Int Forum Allergy Rhinol. 2014;4(5):381–389. https://doi.org/10.1002/alr.21309.

38. Korkmazov AM, Dubinets ID, Lengina MA. Possibilities of topical antioxidant protection of operated cavities in practical otorhinolaryngology. Vestnik Oto-Rino-Laringologii. 2017;82(S5):14–15. (In Russ.) Available at: https://elibrary.ru/ylwhjs.

39. Krivopalov AA, Moroz NV, Belicheva EG, Lengina MA. Phage therapy in overcoming antibiotic resistance in chronic rhinosinusitis. Vestnik OtoRino-Laringologii. 2023;88(6):48–55. (In Russ.) https://doi.org/10.17116/otorino20238806148.

40. Savlevich EL, Brodovskaya OB, Remizova II, Chistjakova GN, Ishchenko AM, Simbirtsev AS. Clinical and immunological aspects of the application of the new aerosol form of recombinant interferon α2b in the treatment of patients with acute nasopharingitis. Citokiny i Vospalenie. 2010;9(1):49–56. (In Russ.) Available at: https://elibrary.ru/ogagej.

41. Lund VJ, Kennedy DW. Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl. 1995;167:17–21. Available at: https://pubmed.ncbi.nlm.nih.gov/7574265/.

42. Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997;117(S3):S35–S40. https://doi.org/10.1016/S0194-59989770005-6.

43. Pan L, Liu Z. Classification of chronic rhinosinusitis with nasal polyps based on eosinophilic inflammation. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;54(3):222–226. https://doi.org/10.3760/cma.j.issn.16730860.2019.03.013.

44. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1–464. https://doi.org/10.4193/rhin20.600.